The double-edged sword: Neurotoxicity of chemotherapy Journal Article


Authors: Magge, R. S.; Deangelis, L. M.
Article Title: The double-edged sword: Neurotoxicity of chemotherapy
Abstract: The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both central and peripheral nervous system toxicities, potentially limiting a patient's ability to tolerate a full course of treatment. Neurotoxicity with chemotherapy is common and second only to myelosuppression as a reason to limit dosing. This review addresses the neurotoxicity of newly available therapeutic agents including brentuximab vedotin and blinatumomab as well as classic ones such as methotrexate, vinca alkaloids and platinums. Although peripheral neuropathy is common with many drugs, other complications such as seizures and encephalopathy may require more immediate attention. Rapid recognition of adverse neurologic effects may lead to earlier treatment and appropriate adjustment of dosing regimens. In addition, knowledge of common toxicities may help differentiate chemotherapy-related symptoms from actual progression of cancer into the CNS. © 2014 Elsevier Ltd.
Keywords: cancer chemotherapy; leukemia; fludarabine; lenalidomide; thalidomide; fatigue; paresthesia; review; cisplatin; drug dose reduction; drug safety; drug withdrawal; solid tumor; unspecified side effect; chemotherapy; cytarabine; methotrexate; rituximab; neurotoxicity; carboplatin; unindexed drug; bortezomib; multiple myeloma; sensory neuropathy; nausea; neuropathy; vomiting; myalgia; peripheral neuropathy; tinnitus; delirium; extrapyramidal symptom; sedation; cyclophosphamide; vincristine; carmustine; procarbazine; vinblastine; hodgkin disease; backache; dizziness; fever; cause of death; confusion; hematologic malignancy; nonhodgkin lymphoma; heart infarction; lymphoma; hernia; dementia; hematopoietic cell; brain disease; bleomycin; chimeric antigen receptor; vindesine; nitrosourea; cognitive defect; lymphoproliferative disease; progressive multifocal leukoencephalopathy; seizure; weakness; headache; vestibular disorder; large cell lymphoma; eye disease; somnolence; toxicity; aphasia; navelbine; oxaliplatin; coma; encephalitis; psychosis; cyclosporin a; lethargy; brain ischemia; neurologic disease; tremor; amnesia; ataxia; brain hemorrhage; hemiparesis; visual impairment; hearing impairment; autonomic neuropathy; leukoencephalopathy; chlorambucil; azacitidine; cranial neuropathy; sensorimotor neuropathy; cell transplantation; myeloma; spinal cord disease; cerebrovascular accident; vascular disease; electrolyte disturbance; paralysis; brain infarction; muscle cramp; cladribine; carfilzomib; motor neuropathy; ototoxicity; randomized controlled trial (topic); nystagmus; phase 2 clinical trial (topic); phase 1 clinical trial (topic); posterior reversible encephalopathy syndrome; kidney dysfunction; aseptic meningitis; dysarthria; engraftment syndrome; brachial plexus neuropathy; anosmia; nelarabine; cerebellum disease; pomalidomide; ageusia; acute brain disease; cerebral blindness; brentuximab vedotin; blinatumomab; horner syndrome; encephalopathy; human; priority journal; neck malformation; bulbar paralysis; high frequency hearing loss; lhermitte symptom; locked in syndrome; neuromuscular junction disorder; transient global amnesia
Journal Title: Blood Reviews
Volume: 29
Issue: 2
ISSN: 0268-960X
Publisher: Churchill Livingstone  
Date Published: 2015-03-01
Start Page: 93
End Page: 100
Language: English
DOI: 10.1016/j.blre.2014.09.012
PROVIDER: scopus
PUBMED: 25445718
PMCID: PMC5944623
DOI/URL:
Notes: Export Date: 3 August 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Rajiv Magge
    2 Magge
Related MSK Work